Scholarlink

<p>Tirzepatide, a dual GIP and GLP-1 receptor agonist, has shown significant metabolic benefits and weight reduction, but its anti-inflammatory effects have been less studied.&#xa0;This study was conducted in accordance with PRISMA guidelines, including observational (cohort) studies and randomized clinical trials that evaluated tirzepatide use and reported percentage changes in high-sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6). A random-effects model was used.&#xa0;Seven randomized clinical trials and one observational study were included (six studies were eligible for meta-analysis). Compared to placebo, tirzepatide reduced hsCRP (mean difference [MD]: −32.9; 95% confidence interval [CI]: −33.6 to − 32.2; I²=15.3%) and IL-6 (MD: −17.8; 95% CI: −24.3 to − 11.3; I² = 1.6%). Levels of hsCRP were significantly reduced with tirzepatide at 15&#xa0;mg (MD: −32.9; 95% CI: −33.6 to − 32.2; I²=4.4%), 10&#xa0;mg (MD: −33.9; 95% CI: −50.3 to − 17.6; I²=41.8%), and 5&#xa0;mg (MD: −20.3; 95% CI: −35.2 to − 5.3; I²=0%). Similarly, IL-6 levels were significantly reduced with tirzepatide at 5&#xa0;mg (MD: −18.8; 95% CI: −32.9 to − 4.6; I²=17.2%), 10&#xa0;mg (MD: −17.9; 95% CI: −28.2 to − 7.7; I²=2.1%), and 15&#xa0;mg (MD: −16.8; 95% CI: −31.1 to − 2.6; I²=47.4%).&#xa0;This study demonstrated that tirzepatide use is associated with a significant reduction in inflammatory markers, regardless of the population studied or treatment regimen.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Anti-inflammatory effects of tirzepatide: a systematic review and meta-analysis

  • 期刊论文

  • 发表日期：

    2025年10月1日

查看全文
  • Walter Masson,
  • Martín Lobo,
  • Juan P. Nogueira,
  • Leandro Barbagelata,
  • Pedro Touzas,
  • Juan P. Frías

摘要

Tirzepatide, a dual GIP and GLP-1 receptor agonist, has shown significant metabolic benefits and weight reduction, but its anti-inflammatory effects have been less studied. This study was conducted in accordance with PRISMA guidelines, including observational (cohort) studies and randomized clinical trials that evaluated tirzepatide use and reported percentage changes in high-sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6). A random-effects model was used. Seven randomized clinical trials and one observational study were included (six studies were eligible for meta-analysis). Compared to placebo, tirzepatide reduced hsCRP (mean difference [MD]: −32.9; 95% confidence interval [CI]: −33.6 to − 32.2; I²=15.3%) and IL-6 (MD: −17.8; 95% CI: −24.3 to − 11.3; I² = 1.6%). Levels of hsCRP were significantly reduced with tirzepatide at 15 mg (MD: −32.9; 95% CI: −33.6 to − 32.2; I²=4.4%), 10 mg (MD: −33.9; 95% CI: −50.3 to − 17.6; I²=41.8%), and 5 mg (MD: −20.3; 95% CI: −35.2 to − 5.3; I²=0%). Similarly, IL-6 levels were significantly reduced with tirzepatide at 5 mg (MD: −18.8; 95% CI: −32.9 to − 4.6; I²=17.2%), 10 mg (MD: −17.9; 95% CI: −28.2 to − 7.7; I²=2.1%), and 15 mg (MD: −16.8; 95% CI: −31.1 to − 2.6; I²=47.4%). This study demonstrated that tirzepatide use is associated with a significant reduction in inflammatory markers, regardless of the population studied or treatment regimen.